Citations

Clear

13 citation(s) found for "Smith, Brian".

Digital imaging analysis to assess scar phenotype
Smith, Brian J., Nidey, Nichole , Miller, Steven F. , Uribe, Lina M. Moreno , Baum, Christian L. , Wehby, George L. , Smith, Brian J., Hamilton, Grant , Dunnwald, Martine

Mayo Clinic

Wound Repair and Regeneration | March 17, 2014 | Volume: 22 | Issue: 2 | Pages: 228-238

10.1111/wrr.12141 | PMID 24635173 Get It

AbstractIn order to understand the link between the genetic background of patients and wound clinical outcomes, it is critical to have a reliable method to assess the phenotypic characteristics of healed wounds. In this study, we present a novel imaging method that provides reproducible, sensitive, and unbiased assessments of postsurgical scarring. We used this approach to investigate the possibility that genetic variants in orofacial clefting genes are associated with suboptimal healing. Red‐green‐blue digital images of postsurgical scars of 68 patients, following unilateral cleft lip repair, were captured using the 3dMD imaging system. Morphometric and colorimetric data of repaired regions of the philtrum and upper lip were acquired using ImageJ software, and the unaffected contralateral regions were used as patient‐specific controls. Repeatability of the method was high with intraclass correlation coefficient score > 0.8. This method detected a very significant difference in all three colors, and for all patients, between the scarred and the contralateral unaffected philtrum (p ranging from 1.20−05 to 1.95−14). Physicians’ clinical outcome ratings from the same images showed high interobserver variability (overall Pearson coefficient = 0.49) as well as low correlation with digital image analysis results. Finally, we identified genetic variants in TGFB3 and ARHGAP29 associated with suboptimal healing outcome.
A phase I trial of immunostimulatory CpG 7909 oligodeoxynucleotide and 90yttrium ibritumomab tiuxetan radioimmunotherapy for relapsed B‐cell non‐Hodgkin lymphoma
Wiseman, Gregory A., Maurer, Matthew J. , Micallef, Ivana N. , Nowakowski, Grzegorz S. , Ansell, Stephen M. , Inwards, David J. , Porrata, Luis F. , Link, Brian K. , Johnston, Patrick B. , Allmer, Cristine, Asmann, Yan W. , Ballas, Zuhair K. , Smith, Brian J., Weiner, George J. , Witzig, Thomas E. , Habermann, Thomas M. , Colgan, Joseph P. , Zent, Clive S. , Shanafelt, Tait D. , Gupta, Mamta , Smith, Brian J., Maurer, Matthew , Link, Brian K , Weiner, George

Mayo Clinic

American Journal of Hematology | April 26, 2013 | Volume: 88 | Issue: 7 | Pages: 589-593

10.1002/ajh.23460 | PMID 23619698 Get It

Radioimmunotherapy (RIT) for relapsed indolent non‐Hodgkin lymphoma produces overall response rates (ORR) of 80% with mostly partial remissions. Synthetic CpG oligonucleotides change the phenotype of malignant B‐cells, are immunostimulatory, and can produce responses when injected intratumorally and combined with conventional radiation. In this phase I trial, we tested systemic administration of both CpG and RIT. Eligible patients had biopsy‐proven previously treated CD20+ B‐cell NHL and met criteria for RIT. Patients received rituximab 250 mg/m2 days 1,8, and 15; 111In‐ibritumomab tiuxetan days 1, 8; CpG 7909 days 6, 13, 20, 27; and 0.4 mCi/kg of 90Y‐ibritumomab tiuxetan day 15. The doses of CpG 7909 tested were 0.08, 0.16, 0.32 (six patients each) and 0.48 mg/kg (12 patients) IV over 2 hr without dose limiting toxicity. The ORR was 93% (28/30) with 63% (19/30) complete remission (CR); median progression free survival of 42.7 months (95% CI 18‐NR); and median duration of response (DR) of 35 months (4.6–76+). Correlative studies demonstrated a decrease in IL10 and TNFα, and an increase in IL1β, in response to therapy. CpG 7909 at a dose of 0.48 mg/kg is safe with standard RIT and produces a high CR rate and long DR; these results warrant confirmation. Am. J. Hematol. 88:589–593, 2013. © 2013 Wiley Periodicals, Inc.
EUDOC on the IBM Blue Gene/L system: Accelerating the transfer of drug discoveries from laboratory to patient
Pang, Yuan‐Ping , Mullins, Tim, Swartz, Brent, McAllister, J. S., Smith, Brian E., Archer, Charles J, Musselman, Roy, Peters, Amanda, Wallenfelt, Brian, Pinnow, K. W., Pang, Yuan-Ping

Mayo Clinic

IBM Journal of Research and Development | April 5, 2010 | Volume: 52 | Issue: 1.2 | Pages: 69-81

10.1147/rd.521.0069 Get It